SAN FRANCISCO — Fair or not, many people look at med-tech stalwart Boston Scientific (Natick, Massachusetts) and they think about a company that has struggled to find its footing after the mammoth $27.5 billion acquisition of Guidant back in 2006. Product recalls and litigation related to that acquisition have dogged the company in recent years, but it appears poised to finally put those issues to rest and emerge as an even stronger company with a compelling and growing product portfolio.